IPA Awarded US$1.5M Bioscience Innovation Grant for Coronavirus Research from the North Dakota Department of Agriculture

07/13/20

Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA’s Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies

06/29/20

IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2

06/22/2020

Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2

06/04/2020

ImmunoPrecise Collaborates with the NIH and Integrated Biotherapeutics to Study the Structural Details of Antibodies with Therapeutic Potential to Treat or Prevent Coronavirus Disease 2019 (COVID-19)